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Abstract
Background: A major challenge faced by countries with a high burden of tuberculosis (TB) is early detection
especially in individuals with paucibacillary disease which is common in HIV endemic settings.
Remarkable efforts have been made globally to accelerate the development and expansion of new diagnostic
technologies that allow better and earlier diagnosis of active tuberculosis particularly directly from clinical specimens
with a few commercial options available. These include GenoType MTBDRplus Version 2.0 (Hain Lifescience), Xpert®
MTB/RIF (Cepheid) and Anyplex™ plus MTB/NTM/DR-TB Real-time detection (Seegene).
We evaluated the diagnostic performance of these three commercial molecular assays for the detection of Mycobacterium
tuberculosis complex from clinical specimens in a high TB-HIV-burden setting.
Methods: This was a retrospective laboratory-based study using stored remnant sediments from clinical specimens of
presumptive pulmonary TB cases. A stratified sample of smear positive TB, smear negative TB and TB culture negatives
was included. All the samples were tested on the three molecular assays following the manufacturers’ instructions; except
for Anyplex™plus, for which DNA extraction was performed using the NucliSENS® easyMAG® platform (bioMerieux).
Samples were also processed for liquid TB culture and time-to-culture positivity was recorded.
Results: Of the 90 sediments processed, 81 were analyzable across all three systems. The overall sensitivity was highest
for Xpert® MTB/RIF (89.1 %) followed by GenoType MTBDRplus (70.9 %) and Anyplex™ plus (65.5 %). The specificity and
sensitivity in smear positive cases was comparable across all systems. There was a significant difference in sensitivity
between Xpert® MTB/RIF and the other two assays for smear-negative cases (P < 0.05). The performance in cases where
the time-to-culture positivity was ≥20 days was also significantly poorer for both Anyplex™ plus and GenoType
MTBDRplus compared to Xpert® MTB/RIF (P < 0.05). Xpert® MTB/RIF achieved 100 % specificity, while Anyplex™
plus and GenoType MTBDRplus achieved 96.2 and 92.3 % respectively.
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Conclusion: The Xpert® MTB/RIF was superior to the other two assays for the detection of TB in smear negative
specimens notably when bacterial loads are very low in sputum. It is important that studies reporting on test
performance stratify their results by time-to-culture positivity to accurately assess clinical performance especially
in high HIV settings.
Keywords: GenoType MTBDRplus, Xpert® MTB/RIF, Anyplex™ plus, Mycobacterium tuberculosis, Detection,
Molecular assays, TB-HIV, South Africa
Background
Tuberculosis (TB) has plagued humankind for thousands
of years [1]. It still remains a major global public health
challenge despite being declared by the World Health
Organization (WHO) more than twenty years ago, as a
public health emergency [2]. In 2012, the case detection
rate was 66 % worldwide, which is below the minimum
70 % target [2]. One of the major reasons for this short-
fall is the lack of accurate and reliable diagnostic tools [3].
In most resource-limited countries, conventional
smear microscopy is the most widely used primary la-
boratory method for TB diagnosis [4]. Although
cheap and relatively easy to perform; this century old
method has variable sensitivity rates ranging from 32
to 94 % [5]. The sensitivity often depends on the dili-
gence with which the specimens are collected and
processed [4]. The modification of smear microscopy,
which includes, physical and chemical processing
methods and the use of fluorescence microscopy has
improved sensitivity with specificity remaining com-
parable [5, 6]. This is especially relevant among chil-
dren and people living with human immunodeficiency
virus (HIV) with smear-negative pulmonary TB [5–7].
Over the years, there has been significant advance-
ment in molecular technologies, particularly develop-
ment of real-time polymerase chain reaction (PCR)
testing platforms. The main advantages of real-time
PCR are shortened turn-around-time, automation of
the procedure which reduces hands-on time and risk
of cross-contamination [3, 4, 8]. There are currently
two WHO-endorsed molecular technologies, namely,
GenoType MTBDRplus (Hain Lifescience GmbH,
Nehren, Germany) and Xpert® MTB/RIF (Cepheid,
USA) [2]. New molecular tests are increasingly being
developed for the diagnosis of TB, thus, TB programs
and diagnostic laboratories are often faced with the
dilemma of choosing between the molecular options
available.
GenoType MTBDR assay (Hain Lifescience GmbH,
Nehren, Germany) was introduced in 2004 and is a
PCR amplification and reverse hybridization assay that
simultaneously detects M. tuberculosis complex
(MTBC) as well as mutations in the rpoB gene for
rifampicin resistance and the katG gene for high-level
isoniazid resistance [9]. The second generation assay,
GenoType MTBDRplus detects in addition mutations
in the inhA gene that confer low-level isoniazid resist-
ance [9, 10]. GenoType MTBDRplus version 1.0 has
been proven to be robust and accurate but limited to
smear-positive or culture positive isolates [10]. The
assay was endorsed by the WHO in 2008, with the
intention to enhance capacity for rapid diagnosis of
drug resistant tuberculosis and reviewed in a meta-
analysis by Ling and colleagues [2, 9]. GenoType
MTBDRplus version 2.0 has been released for use in
smear-negative specimens, which provides an oppor-
tunity to exclude the culture step thus reducing the
turnaround time and has demonstrated a sensitivity
of 56.6 % in smear-negative TB cases in the South
African setting [11].
The Xpert® MTB/RIF endorsed by WHO in 2010, is an
automated hemi-nested real-time PCR assay that simul-
taneously detects Mycobacterium tuberculosis complex
and rifampicin resistance [12–14]. This is a simple assay
that can be performed with minimal training and provides
results within two hours, including a 15-minute manual
sample preparation step [12–14]. Steingart et al. demon-
strated a pooled sensitivity of 98 % for smear-positive
cases and 67 % for smear-negative TB cases [12].
The Anyplex™ plus MTB/NTM/DR-TB (Seegene,
Seoul, Republic of Korea) is a commercially available
multiplex real-time PCR system but not endorsed by the
WHO. The assay uses two technologies, namely, the
Dual Priming Oligonucleotide (DPO™) technology and
the Real Amplicon Detection (READ) technology [15].
These technologies enable the test to perform multi-
target detection with high specificity and sensitivity [15].
The DPO™ technology provides freedom in primer de-
sign and PCR optimization and maximizes PCR sensitiv-
ity and specificity by blocking non-specific priming [15].
The READ technology allows high-throughput multi-
plexing onto a real-time PCR platform [15]. The assay is
a two-step open system that detects MTB/NTM first.
Drug susceptibility testing for MTBC is a second PCR
reaction that is not continuous with the MTB/NTM de-
tection step. Thus, amplicons generated in the MTB/
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NTM detection step need to be manually pipetted to a
second PCR reaction for assessment of drug susceptibility.
A comparison of the three molecular systems is shown in
Table 1. To our knowledge, there have been no published
studies evaluating the performance of Anyplex™ plus
MTB/NTM/DR-TB in a high TB-HIV-burden setting.
We evaluated the diagnostic performance of these
three commercial molecular assays for the detection of
Mycobacterium tuberculosis complex (MTBC) from clin-
ical specimens in a high TB-HIV-burden setting.
Methods
This study was conducted at the National Health
Laboratory Service (NHLS) diagnostic microbiology la-
boratory (TB section), Tshwane Academic Division,
Pretoria, South Africa. This is an ISO 15189 accredited
laboratory at a tertiary academic institution and provides
TB diagnostic services to tertiary and district hospitals,
and surrounding primary health care clinics. This was a
laboratory based retrospective study which did not have
prior informed patient consent when samples were rou-
tinely collected for TB investigations, and it was not
feasible to acquire the consent retrospectively. We re-
quested and received a waiver of informed consent from
the Health Research Ethics Committee at the University
of Pretoria, which is an accredited ethics committee
(Ethics Reference No.: 445/2013).
Remnant sediments from presumptive pulmonary TB
cases submitted for TB investigations, which included
fluorescent TB microscopy and culture were retrieved
from the departmental storage section; stored at 2–8 °C
for a maximum of 3 months. Sediments with at least
3.5 ml volume were included, and we selected sequential
culture positive and culture negative sediments in a 2:1
ratio with a total sample size of 90 sediments; 60 culture
positive and 30 culture negative.
These sediments were from respiratory samples proc-
essed following the laboratory’s standard operating proce-
dures. Briefly, after digestion with dithiotreitol-containing
digestant and centrifugation at 3000 × g for 20 min, an ali-
quot of the sediment was subjected to smear microscopy
using the auramine-O fluorescence stain. The smears were
graded according to the International Union Against Tu-
berculosis and Lung Disease (IUATLD) guidelines. All the
digested samples were then decontaminated with initial
concentration of 4 % sodium hydroxide solution and
allowed to stand for 25 min at room temperature. The
phosphate buffer was then added to dilute the mixture and
centrifuged at 3000 × g for 20 min. The remnant sediments
were split into three aliquots of 1 ml each and randomly
assigned to one of the three assays to minimize bias. A
0.5 ml aliquot was inoculated into the BACTEC™ MGIT™
960 Mycobacterial Detection System (BD Diagnostics,
USA) to reconfirm the culture results and incubated for a
maximum of 42 days. Positive cultures were confirmed to
be mycobacteria by performing Ziehl-Neelsen (ZN) stain-
ing, and as MTBC using the TB Ag MPT64 Rapid (SD Bio-
line, South Korea). If the ZN was negative for acid fast
bacilli, this was regarded as a contaminated culture. No
further re-decontamination was attempted on any of the
positive MGIT cultures. Time-to-culture-positivity (TTP)
of the primary culture was recorded and regarded as final.
Testing on the three molecular platforms, namely,
Anyplex™ plus MTB/NTM/DR-TB Real-time detection
(Anyplex™plus), GenoType MTBDRplus version 2.0
(MTBDRplus) with GenoLyse® extraction, and Xpert®
MTB/RIF (Xpert®) followed the manufacturers’ instruc-
tions; except for extraction of Anyplex™plus. For the
latter, DNA extraction was performed using the Nucli-
SENS® easyMAG® platform (bioMerieux, France), using
the generic protocol, as initial preparatory work indi-
cated that the extraction procedure as prescribed by the
manufacturer was not optimal resulting in PCR inhib-
ition. Invalid results on any of the three assays were re-
peated and excluded if they remained invalid.
All the results were tabulated according to smear and
culture status. Sensitivity was calculated as proportion of
positives over the true positives for each stratum (scanty
Table 1 Comparison of operational characteristics the three molecular assays
Anyplex™ plus MTB/NTM/DR-TB GenoType MTBDRplus version 2.0 Xpert® MTB/RIF
Principle Two-step multiplex real time PCR Reverse hybridisation Hemi-nested real-time PCR
End result MTBC, NTM, RIF, INH MTBC, RIF, INH MTBC, RIF
Level of complexity High High Low
Turn-around-time
(including DNA extraction)
3.5 h 5.35 h 2 h
Result interpretation Automated Manuala Automated
Throughput per run 96 48 16b
Laboratory infrastructure Open system requiring three
separate work areas.
Open system requiring three
separate work areas.
Closed system, bench top within a
temperature controlled area
aGenoscan required for automated interpretation of results but at an additional cost
bDepends on which module you have (e.g. 4, 16, or 48)
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positive, smear positive and negative). Specificity was
calculated as a proportion of negatives over true neg-
atives. Additionally, the sensitivity calculation was
performed on smear negative sediments for those
with a TTP of less than 20 and 20 days or more. A
McNemar test for symmetry was used to assess sig-
nificant differences between the performance of each
test and a P value of ≤0.05 was considered significant.
Bivariate correlation was performed comparing TTP
and Xpert® cycle threshold (Ct) score for the smear
negative TB cases.
Results
Of the 90 sediments processed, nine were excluded
from analysis because of culture contamination (8) or
invalid result (1), thus 81 results were analyzable
across all three systems resulting in 55/60 (91.7 %)
culture positive and 26/30 (86.7 %) culture negative.
Of the culture positive, 29/55 (52.7 %) were smear
positive; six being scanty positive and the remaining
26 smear negative cases.
The overall sensitivity was highest for Xpert® at
89.1 % followed by MTBDRplus at 70.9 % and Any-
plex™ plus at 65.5 % (Table 2). The specificity across
all systems was comparable with Xpert® achieving the
highest specificity (100 %). Among the smear positive
cases, Anyplex™ plus unlike the other two systems
had false negative results for 2/23 cases.
There was a significant difference in sensitivity
between Xpert® and the other two assays for smear-
negative cases (P < 0.05). Among the smear negative
cases, 12 were culture positive within 20 days and 14
were positive at day 20 or later. The performance of
smear-negative cases was 75 % or higher in isolates with
a TTP of less than 20 days across all systems with no
significant difference (P = 0.5) (Table 3). However, the
performance in cases where the TTP was ≥20 days was
significantly poorer for both Anyplex™ plus and
MTBDRplus compared to Xpert® (P < 0.05) (Table 3).
There was no correlation (r = 0.08) between the Xpert
Ct scores and the TTP among the smear negative TB
cases (Table 4).
Discussion
This study was the first to directly compare these three
commercially available assays in a high HIV and TB preva-
lence setting and demonstrated that Xpert® had the best
overall performance for the detection of TB from clinical
specimens. The Xpert®, MTBDRplus and Anyplex™ plus
showed overall sensitivities of 89.1 %, 70.9 and 65.5 % re-
spectively. The performance of the Xpert® MTB/RIF in
our study is comparable with a meta-analysis by Steingart
et al. showing a pooled sensitivity of 98 % for smear posi-
tive cases, however, for the smear negative cases the sensi-
tivity in our study was higher (80 % vs 67 %) [12].
Although our study showed comparable overall sensitivity
for Xpert® with published literature; it was not the case for
the other two assays. However, when restricted to TTP of
less than 20 days, their performances are comparable to
those in the literature. All three assays failed to detect six
(10.9 %) culture-positive TB cases; five smear-negative and
one scanty-positive which influenced their overall sensitiv-
ities. These isolates had a mean TTP of 23 days (range
19–30 days) suggesting that the number of bacilli in these
specimens was low.
Time-to-liquid culture positivity has been shown to be
an alternative measure of bacterial burden and has an in-
verse correlation with the number of colony forming units
on solid media and bacilli on microscopy [16, 17]. An im-
portant finding in our study was the significant differences
in sensitivity rates of smear negative cases with TTP of
20 days or longer. This was not observed in smear positive
cases or smear negative cases with TTP of less than 20 days
which indicates that the superior performance of Xpert®
for TB detection is due to its ability to detect low bacillary
loads compared to the other assays and further corrobo-
rated by the low level of detection of the assay. However,
when the average Ct scores in the smear negative group
were compared between those with a TTP <20 days to
those with a TTP ≥20 days there was no correlation. This
could be explained by the fact that the Xpert® system, has a
Table 2 Performance of the molecular assays compared to culture
Category Anyplex™ plus MTB/NTM/DR-TB GenoType MTBDRplus version 2.0 Xpert® MTB/RIF
Sensitivity (culture positive for MTB)
Overall sensitivity (n = 55) 36 (65.5 %) 39 (70.9 %) 49 (89.1 %)
Smear Positive (n = 23) 21 (91.3 %) 23 (100 %) 23 (100 %)
Scanty Positive (n = 6) 3 (50 %) 4 (66.7) 5 (83.3 %)
Smear negative (n = 26) 12 (46.2 %) 12 (46.2 %) 21 (80.8 %)*
Specificity
Culture negative (n = 26) 25 (96.2 %) 24 (92.3 %) 26 (100 %)
*P < 0.05 when Xpert® is compared to Anyplex™ plus and when Xpert® is compared to MTBDRplus
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filter capture system that concentrates M. tuberculosis
bacilli and is a hemi-nested real time assay which
aims to increases test sensitivity but this 2 stage
cycling approach means that the Ct scores reported
may not directly relate to the original bacterial load.
This methodology would be especially true when the
original bacterial load is low. Furthermore, Omar et
al. showed no correlation between mean Ct scores for
concentrations of M. tuberculosis between 25 and
2500 CFU/ml, which relates to smear negative cases
[18].
MTBDRplus has been evaluated for diagnosis of
smear-negative TB cases and has had variable perform-
ance rates in different settings. Crudu et al. demon-
strated a sensitivity rate of 76 % when MTBDRplus was
compared to culture as the gold standard in a setting
with an estimated 4.7 % prevalence of TB/HIV co-
infection in 2009 [19]. Barnard et al. reported 56.6 % de-
tection rate of smear-negative TB cases in a high TB and
HIV prevalence setting [11]. In our study with an even
high rate of HIV population prevalence than the Barnard
paper (12.4 % compared with 5 %), we reported an over-
all sensitivity of 46.2 % which is lower compared to the
other studies [20]. However, when restricted to TTP of
Table 3 Sensitivities of the molecular assays based on Time-To-










<20 days (n = 12) 9 (75 %) 9 (75 %) 11 (91.2 %)
≥20 days (n = 14) 3 (21 %) 3 (21 %) 10 (71 %)*
*P < 0.05 when Xpert® is compared to Anyplex™ plus and when Xpert® is
compared to MTBDRplus
Table 4 Comparison of Xpert® Ct scores and Time-To-Culture Positivity (TTP)
Study Number TTP Probe D Probe C Probe E Probe B Probe A Xpert® interpretation Ave Ct
TTP <20d
138 11 20.8 19.3 20.8 21.3 19.2 Medium 20.28
122 14 20.9 19 20 22.3 18.6 Medium 20.16
127 14 14.7 13.3 15.2 14.9 13.2 High 14.22
130 14 16.5 15.1 16.5 16.6 14.9 High 15.92
132 14 20.7 19.2 20.6 20.3 19 Medium 19.96
142 14 17.9 16.6 18.1 0 16.5 Medium 13.82
144 15 26.3 25.0 26.3 26.3 24.7 Low 25.72
147 15 26.7 25.5 27.1 26.6 25.4 Low 26.26
131 16 28.1 26.6 28.2 28.1 26.6 Low 27.52
139 16 34 33 34.8 33.3 33 Low 33.62
121 18 32.9 31.8 33.7 32.2 32.1 Very Low 32.54
145 19 Not detected
TTP ≥20d
133 20 23.2 21.7 23.2 23.2 21.6 Medium 22.58
136 21 Not detected
146 21 26.9 25.4 26.9 26.9 25.4 Low 26.3
120 21 20.4 18.8 20.1 20.3 18.7 Medium 19.66
124 21 35.1 33.8 36.1 34.3 34.1 Very Low 34.68
125 21 33.7 32.5 34.5 33.0 32.6 Very Low 33.26
126 21 Not detected
137 21 Not detected
128 22 27.3 25.9 27.3 27.4 25.8 Low 26.74
129 22 23.6 22.1 23.6 23.5 22.0 Medium 26.74
134 22 21.3 19.7 21.2 21.2 19.5 Medium 20.58
119 23 26.9 25.8 27 26.7 25.6 Low 26.4
135 26 24.1 22.8 24.1 24.1 22.5 Low 23.52
123 30 Not Detected
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less than 20 days, sensitivity is comparable with that
demonstrated by Crudu et al. [19]. Our study possibly
explains the performance variability of MTBDRplus in
different settings and patient population differences es-
pecially related to the relative risk of paucibacillary dis-
ease in patients being sampled. The inconsistency in the
performance of MTBDRplus for smear-negative TB
cases in different settings illustrates its limited value in
these cases.
Lim et al. prospectively evaluated the performance of
Anyplex™ plus against culture for respiratory specimens
in a high-TB-burden setting and reported overall sensi-
tivity of 87.5 and 69.2 % for smear-negative TB cases
[21]. Perry et al. evaluated the performance of Anyplex™
plus against culture in a low-TB-burden setting in two
arms; retrospective and prospective arms [22]. They re-
ported sensitivity and specificity of 86 and 99 % respect-
ively in the retrospective arm, and 100 and 96 %
respectively in the prospective arm [22]. Both these stud-
ies were conducted in low HIV-burden setting and
showed sensitivities higher than what we found. Despite
novel technology in the assay and the improved extrac-
tion method utilized in our study, the assay had the low-
est sensitivity.
Xpert® achieved 100 % specificity while MTBDRplus
and Anyplex™ plus detected the presence of TB in
culture-negative isolates. One isolate was positive on
both assays and negative on Xpert®. Upon reviewing of
laboratory records, this isolate was found to be from a
patient with previous laboratory confirmed TB. The rea-
son for the other false positive case detected only on
MTBDRplus is unknown. False positive results on mo-
lecular assays have been attributed to the presence of
non-viable organisms either due to patients being on
treatment, thus, these assays are not recommended for
monitoring response to therapy [23–25] or could also be
due to inadequate buffering in the preparatory step for
culture. Alternatively as these are open systems, labora-
tory cross-contamination is also a possibility [23]. Other
reasons include a low mycobacterial load with concomi-
tant harsh decontamination of the sample. Clinical inter-
pretation would need to be assessed on a case to case
basis reviewing previous diagnosis for TB as well as re-
peat testing.
There is no diagnostic test without flaws but mo-
lecular assays offer the potential for sensitive, specific
and timely diagnosis. Xpert® offers in addition suscep-
tibility to rifampicin which is used as a surrogate
marker for multi-drug-resistant TB (MDR-TB) [12,
13]. This assay provides rapid results with minimal
hands-on time and low potential for PCR contamin-
ation [12–14]. Unfortunately, the assay suffers a series
of limitations; it requires an ambient temperature of
<30 °C, storage space for the cartridges, uninterrupted
supply of electric power which may not always be
available in developing countries and the cost of
waste disposal [14]. MTBDRplus has a potential risk
of contamination through post-amplification process-
ing and its interpretation of results is subjective if
performed manually [11]. The interpretation of results
is based on visual inspection of the strips and there
can be inter-observer variation resulting in inconsist-
ent reporting of results. We found MTBDRplus to be
more labour-intensive as compared to Anyplex™ plus
and Xpert®. Additionally, MTBDRplus and Anyplex™
plus require highly trained staff, sophisticated equip-
ment and laboratory infrastructure. Anyplex™ plus of-
fers rapid identification of non-mycobacterial
tuberculosis (NTM) and may reduce the time and
health-care cost associated with false-positive TB
diagnosis based on smear microscopy. As mentioned
earlier, Anyplex™ plus is an open two-step PCR assay
and may increase chances of laboratory cross contam-
ination. Anyplex™ plus may offer an alternative option
particularly in low TB burden settings where very few
cases of TB (less likely drug-resistant TB) are ex-
pected. In our study, we used the NucliSens® easy-
MAG® for extraction because we observed PCR
inhibition when the manufacturer’s recommended
method was followed. This resulted in additional cost
to the assay. DNA extracted using the recommended
method in MTBDRplus version 1.0 may be used on
Anyplex™ plus as demonstrated by Perry et al. [22].
The limitation in our study is the use of stored re-
sidual specimens and we did not apply a final buffer-
ing step. Prior handling of the specimens as opposed
to usage directly after decontamination might have
compromised the quality of the specimens and thus
the performance of the assays. However, we had dir-
ectly compared the three assays which would not
have been possible without testing from sediment. In
addition, we used stored samples as we wanted to
have an economical way of testing smear negative TB
cases across all three systems, which are of import-
ance in high HIV settings. An additional point to note
is that our standard two stage laboratory sample pro-
cessing applies centrifugation twice thus potentially
enhancing the performance of the systems evaluated.
Conclusion
Xpert® performed the best overall and was also superior
in samples with low bacillary load as evidenced by its
performance in TTP of 20 days or longer. The findings
of our study supports the current WHO endorsement of
Xpert® for smear negative TB. It is important that studies
reporting on test performance stratify their results by
TTP to accurately assess clinical performance especially
in high HIV settings.
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